Save

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

PHASE1RECRUITING

This study is to evaluate the safety and tolerability of EMB-09 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-09 will also be assessed.

Simpliy with AI

Study details:

This is a phase I, multi-center, open label, multiple dose, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose for EMB-09 in patient with advanced or metastatic solid tumors. Pharmacokinetics,pharmacodynamics, immunogenicity and response will also be assessed.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.

Phase I subjects: 1. Patients with histologically or cytologically confirmed locally advanced/metastatic solid tumors including but not limited to melanoma, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal cancer (NPC), hepatocellular carcinoma (HCC), gastric cancer (GC), endometrium cancer (EC), ovarian cancer (OC), renal cell carcinoma (RCC) and small cell lung cancer (SCLC), colorectal cancer (CRC). 2. Patients who have failed (progressed on, or are intolerant of) standard therapies or no available standard treatment 3. Measurable or evaluable disease per RECIST v1.1.

Patients must provide archival tumor, or a fresh tumor biopsy will be required if archival tumor sample is not available. Archival tumor sample must be taken <2 years prior to screening, otherwise a fresh tumor biopsy at screening is required.

ECOG performance status 0 or 1; life expectancy > 3 months.

Adequate organ function to participate in the trial.

Recovery from adverse events (AEs) related to prior anticancer therapy.

Highly effective contraception

Exclusion criteria

Patients who have active autoimmune disease or history of autoimmune disease

History of severe irAE.

History of severe allergic reactions

Use of systemic corticosteroids.

Symptomatic central nervous system metastases.

Patients with cardiac dysfunction

Uncontrolled diabetes mellitus with hemoglobin A1c > 8% (via medical history)

Prior treatment with TNFRSF agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR), CD40.

Anticancer therapy or radiation < 5 half-lives or 4 weeks (whichever is shorter) prior to study treatment;

Current or history of idiopathic pulmonary fibrosis, interstitial lung disease, or organizing pneumonia.

Concurrent malignancy < 5 years prior to entry.

Patients with active infections.

Major surgery < 4 weeks or minor surgery < 2 weeks prior to study treatment.

Live virus vaccines < 30 days prior to screening

Pregnant or breast-feeding females

Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment.

Any other serious underlying medical conditions

Abuse of alcohol, cannabis-derived products, or other drugs.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2022-07-25

Primary completion: 2023-12-31

Study completion finish: 2024-12-31

Study type

TREATMENT

Phase

PHASE1

Trial ID

NCT05263180

Intervention or treatment

BIOLOGICAL: EMB-09

Conditions

• Advanced Solid Tumor

Condition: Advanced Solid Tumor
BIOLOGICAL: EMB-09
Sydney, Not Specified, Australia and more
Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Blacktown Hospital

Research sites nearby

Select from list below to view details:

Blacktown Hospital
Sydney, Not Specified, Australia
Peninsula and South Eastern Haematology & Oncology Group
Frankston, Not Specified, Australia
GenesisCareNorthShore
Leonards Hill, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Experimental: EMB-09 Participants enrolled at different time will receive EMB-09 once a week (IV) at different ascending dose levels.	BIOLOGICAL: EMB-09 EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence and severity of adverse events as assessed by CTCAE V5.0	Incidence and severity of AE.	Screening up to 30 days after the last dose.
Incidence of serious adverse events. (SAE)	Incidence of SAE.	Screening up to 30 days after the last dose, or beyond 30 days if SAE is confirmed to be treatment related.
Incidence of dose interruptions.	Incidence of dose interruptions of EMB-09 during treatment as a measure of tolerability.	Screening up to 30 days after the las dose.
Dose intensity.	Actual amount of drug taken by patients divided by the planned amount.	Screening up to 30 days after the last dose.
The incidence of DLTs during the first cycle of treatment.	The dose limiting toxicities are based on drug related adverse events and are specifically defined in study protocol.	First infusion to the end of cycle 1. (each cycle is 28 days)

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Overall response rate	Measured by RECIST 1.1.	From the date of dosing until the date of first documented progression or date of death from any cause, whichever case first, expected average 6 months.
Area under the serum concentration-time curve (AUC) of EMB-09	Blood samples for serum PK analysis will be obtained (AUC).	Through treatment until EOT visit, expected average 6 months
Maximum serum concentration (Cmax) of EMB-09	Blood samples for serum PK analysis will be obtained (Cmax)	Through treatment until EOT visit, expected average 6 months
Trough concentration (Ctrough) of EMB-09	Blood samples for serum PK analysis will be obtained (Ctrough)	Through treatment until EOT visit, expected average 6 months
Average concentration over a dosing interval (Css, avg)of EMB-09.	Blood samples for serum PK analysis will be obtained (Css, avg).	Through treatment until EOT visit, expected average 6 months
Terminal half-life (T1/2) of EMB-09	Blood samples for serum PK analysis will be obtained (T1/2)	Through treatment until EOT visit, expected average 6 months
Systemic clearance (CL) of EMB-09	Blood samples for serum PK analysis will be obtained (CL).	Through treatment until EOT visit, expected average 6 months
Steady state volume of distribution (Vss) of EMB-09	Blood samples for serum PK analysis will be obtained (Vss).	Through treatment until EOT visit, expected average 6 months
Progression free survival (PFS) of EMB-09 as assessed by RECIST 1	Preliminary anti-tumor activity of EMB-09 will be obtained. (DOR)	From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months
Incidence and titer of anti-drug antibodies stimulated by EMB-09	Antibodies to EMB-09 will be assessed to evaluate potential immunogenicity.	Up to End of Treatment Follow Up Period (30 days after the last dose

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Connect to trial

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.